Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Cardiovascular Drugs and Therapy|October 28, 2018
Dapagliflozin Attenuates Na<sup>+</sup>/H<sup>+</sup> Exchanger-1 in Cardiofibroblasts via AMPK ActivationYumei Ye, Xiaoming Jia, Mandeep Bajaj, et al.
Basic Research in Cardiology|August 8, 2019
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasomeYochai Birnbaum, Dat Tran, Mandeep Bajaj, et al.
Cardiovascular Drugs and Therapy|March 7, 2018
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 DiabetesYochai Birnbaum, Mandeep Bajaj, Hsiu-Chiung Yang, et al.
American Journal of Physiology. Endocrinology and Metabolism|February 15, 2007
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetesKenneth Cusi, Sangeeta Kashyap, Amalia Gastaldelli, et al.
Cardiovascular Drugs and Therapy|February 16, 2018
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome TrialsXiaoming Jia, Mahboob Alam, Yumei Ye, et al.
Metabolic Syndrome and Related Disorders|January 12, 2010
Insulin clamp-derived measurements of insulin sensitivity and insulin secretion in lean and obese asian type 2 diabetic patientsSwangjit Suraamornkul, Rachaneewon Kwancharoen, Mudjalin Ovartlarnporn, et al.
Metabolic Syndrome and Related Disorders|September 22, 2010
Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjectsSangeeta R Kashyap, Linda J Roman, Lawrence Mandarino, et al.
Cardiovascular Drugs and Therapy|February 11, 2016
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion InjuryJinqiao Qian, Hongmei Chen, Yochai Birnbaum, et al.
Cardiovascular Drugs and Therapy|April 28, 2017
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 InhibitorYumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, et al.
Cellular Signalling|September 11, 2013
MicroRNA-dependent cross-talk between VEGF and HIF1α in the diabetic retinaShukuan Ling, Yochai Birnbaum, Manjyot K Nanhwan, et al.
Pageof 6